Advertisement


Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

2017 ASTRO Annual Meeting

Advertisement

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).



Related Videos

Survivorship

James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects

James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4)....

Lung Cancer

Shrinivas Rathod, MD, on NSCLC: Quality-of-Life Outcomes From an IAEA Trial

Shrinivas Rathod, MD, of the University of Manitoba, discusses phase III study results on optimization of treatment of advanced non–small cell lung cancer using radiation therapy a...

Head and Neck Cancer

Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective

Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation ther...

Breast Cancer

Shulian Wang, MD, and Benjamin Movsas, MD, on Breast Cancer: Radiation Therapy After Mastectomy

Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after ma...

Lung Cancer

Maria Werner-Wasik, MD, on Lung Cancer Highlights: Expert Perspective

Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session on NSCLC that included discussion of a quality-of-life trial on optimizing treatment; chemothe...

Advertisement

Advertisement



;
Advertisement